Identification of the Regulatory Targets of miR-3687 and miR-4417 in Prostate Cancer Cells Using a Proteomics Approach.
castration-resistant prostate cancer
cellular regulation
microRNA
prostate cancer
proteomics
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 Sep 2022
12 Sep 2022
Historique:
received:
28
06
2022
revised:
08
09
2022
accepted:
08
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
MicroRNAs (miRNA) are ubiquitous non-coding RNAs that have a prominent role in cellular regulation. The expression of many miRNAs is often found deregulated in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC). Although their expression can be associated with PCa and CRPC, their functions and regulatory activity in cancer development are poorly understood. In this study, we used different proteomics tools to analyze the activity of hsa-miR-3687-3p (miR-3687) and hsa-miR-4417-3p (miR-4417), two miRNAs upregulated in CRPC. PCa and CRPC cell lines were transfected with miR-3687 or miR-4417 to overexpress the miRNAs. Cell lysates were analyzed using 2D gel electrophoresis and proteins were subsequently identified using mass spectrometry (Maldi-MS/MS). A whole cell lysate, without 2D-gel separation, was analyzed by ESI-MS/MS. The expression of deregulated proteins found across both methods was further investigated using Western blotting. Gene ontology and cellular process network analysis determined that miR-3687 and miR-4417 are involved in diverse regulatory mechanisms that support the CRPC phenotype, including metabolism and inflammation. Moreover, both miRNAs are associated with extracellular vesicles, which point toward a secretory mechanism. The tumor protein D52 isoform 1 (TD52-IF1), which regulates neuroendocrine trans-differentiation, was found to be substantially deregulated in androgen-insensitive cells by both miR-3687 and miR-4417. These findings show that these miRNAs potentially support the CRPC by truncating the TD52-IF1 expression after the onset of androgen resistance.
Identifiants
pubmed: 36142477
pii: ijms231810565
doi: 10.3390/ijms231810565
pmc: PMC9501364
pii:
doi:
Substances chimiques
Androgens
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Oncogene. 2012 Oct 11;31(41):4460-71
pubmed: 22266859
Int J Nanomedicine. 2021 Jan 12;16:315-327
pubmed: 33469288
Urol Oncol. 2021 Jun;39(6):368.e1-368.e9
pubmed: 33771409
Cancer Res. 2006 Aug 1;66(15):7390-4
pubmed: 16885332
J Cancer. 2013 May 09;4(5):350-7
pubmed: 23781281
Cancers (Basel). 2021 Jul 11;13(14):
pubmed: 34298683
Urol Oncol. 2014 Jul;32(5):517-523
pubmed: 24935732
Cancer Lett. 2022 Feb 1;526:304-310
pubmed: 34863887
PLoS One. 2015 Jul 21;10(7):e0131232
pubmed: 26196517
J Transl Med. 2022 Jan 3;20(1):6
pubmed: 34980158
PLoS One. 2011 Feb 11;6(2):e16833
pubmed: 21347291
Clin Pharmacol Ther. 2013 Jan;93(1):98-104
pubmed: 23212103
Prostate. 2004 Sep 1;60(4):352-66
pubmed: 15264248
Ann Oncol. 2015 Oct;26(10):2044-56
pubmed: 26101426
IUBMB Life. 2014 Jun;66(6):379-86
pubmed: 24979663
Int J Mol Sci. 2019 Aug 13;20(16):
pubmed: 31412591
Nucleic Acids Res. 2022 Jan 7;50(D1):D687-D692
pubmed: 34788843
Front Chem. 2018 Apr 06;6:108
pubmed: 29682501
Cells. 2020 Apr 22;9(4):
pubmed: 32331346
Clin Chem. 2020 Jun 1;66(6):842-851
pubmed: 32408351
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Oncogene. 2013 Dec 5;32(49):5501-11
pubmed: 23752182
Clin Cancer Res. 2014 Jan 1;20(1):35-43
pubmed: 24146262
Cold Spring Harb Perspect Med. 2018 Jun 1;8(6):
pubmed: 29101113
Tumour Biol. 2016 Aug;37(8):10435-46
pubmed: 26846108
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Prostate. 2015 Jun;75(8):798-805
pubmed: 25731699
Nucleic Acids Res. 2005 Nov 27;33(20):e179
pubmed: 16314309
Res Rep Urol. 2021 Jun 30;13:457-472
pubmed: 34235102
Front Oncol. 2022 May 13;12:913630
pubmed: 35646644
Rom J Morphol Embryol. 2010;51(1):7-12
pubmed: 20191113
Eur Urol. 2012 Jun;61(6):1079-92
pubmed: 22424666
Prostate. 2011 May;71(6):604-14
pubmed: 20945501
PLoS One. 2011;6(7):e21867
pubmed: 21760917
Front Oncol. 2021 Jun 30;11:650054
pubmed: 34277403
Curr Opin Oncol. 2015 May;27(3):209-16
pubmed: 25689354
Oncogene. 2019 May;38(19):3696-3709
pubmed: 30664691
Front Biosci. 1996 Mar 01;1:d59-71
pubmed: 9159212
Nat Rev Genet. 2009 Oct;10(10):704-14
pubmed: 19763153
World J Urol. 2021 Oct;39(10):3789-3797
pubmed: 33990872
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7
pubmed: 21037258
Biomedicines. 2022 Mar 17;10(3):
pubmed: 35327491
Mol Ther Nucleic Acids. 2014 Apr 29;3:e159
pubmed: 24781191
Am J Transl Res. 2012;4(4):432-42
pubmed: 23145211
Elife. 2015 Aug 12;4:
pubmed: 26267216
FEBS Lett. 2015 Jun 4;589(13):1485-90
pubmed: 25936765